Laurence Albiges

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Laurence Albiges
Dec 28, 2024, 13:45 | Insight
FDA Approved Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for subcutaneous injection for…
Dec 15, 2024, 03:39 | Insight
Petros Grivas: Phenomenal talk by Sumanta K. Pal on RCC
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, shared…
Dec 4, 2024, 15:46 | Blog
The CARE1 Principal Investigators team at SOGUG24
CARE1 Project shared on LinkedIn: "The CARE1 Principal Investigators team was proudly present at SOGUG24!…
Nov 9, 2024, 10:58 | Blog
Pavlos Msaouel: Methodological challenges and solutions in estimating os from Randomized Controlled Trials
Pavlos Msaouel, Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center, shared a…
Nov 8, 2024, 18:55 | Insight
Regina Barragan-Carrillo: First and second - line treatments in metastatic renal cell carcinoma
Regina Barragan-Carrillo, Postdoctoral fellow at the Genitourinary Clinic at the Medical Oncology and Medical Therapeutics…
Nov 3, 2024, 12:51 | Insight
Will the future of papillary renal cell carcinoma research offer tricks, or treats?
Uromigos shared a post on X: “Will the future of papillary RCC research offer tricks,…
Oct 11, 2024, 16:03 | Blog
Dimitra Rafailia Bakaloudi: The Uromigos trophy goes to TEAM USA
Dimitra Rafailia Bakaloudi shared a post on X: ''And the Uromigos trophy goes to TEAM…
Oct 8, 2024, 10:06 | Dialogues
ASCO24 Updates: Dr. Laurence Albiges on KIM1: A Promising Biomarker in RCC Treatment
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Sep 10, 2024, 14:54 | Blog
Tom Powles: Belzutifan for clear cell renal cancer
Tom Powles shared a post on X: “Belzutifan significantly outperformed Everolimus in heavily pretreated clear…
Aug 27, 2024, 19:10 | Blog
Petros Grivas: Looking forward to a fantastic ESMO24
Petros Grivas shared a post on X by ESMO, adding: "Looking forward to a fantastic…
Aug 25, 2024, 14:05 | Blog
Petros Grivas: Can’t wait for amazing Uromigos meeting!
Petros Grivas shared a post on X by Uromigos adding: "Can’t wait for amazing Uromigos…
Aug 25, 2024, 13:02 | Insight
Toni Choueiri: Results from LITESPARK-005 are out
Toni Choueiri shared a post on X about a recent paper titled "Belzutifan versus Everolimus…
Aug 24, 2024, 05:36 | Insight
Roberto Iacovelli: Proud of being part of this achievement in renal cancer
Roberto Iacovelli shared on X: “I am so proud of being part of this achievement…
Aug 23, 2024, 11:39 | Opinion
Toni K. Choueiri: LITESPARK-005 is out
Toni K. Choueiri shared on LinkedIn: “LITESPARK-005 is out in NEJM Group —First in class…
Aug 9, 2024, 02:02 | Insight
ASCO24 Abstracts Not To Miss by Earle Burgess
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health, Levine Cancer Institute, recently shared posts on…
Aug 2, 2024, 23:33 | Blog
Renee Maria Saliby: Discussing a huge clinical unmet - non-clear cell RCC
Renee Maria Saliby, Postdoctoral GU Oncology Research Fellow at Dana-Farber Cancer Institute, shared a post by GU…
Jul 13, 2024, 20:46 | Blog
Yüksel Ürün: Outstanding presentation at KCRS24 Rohit Mehra
Yüksel Ürün shared on X: "Outstanding presentation at KCRS 24 Rohit Mehra Role of Pathologist…
Jul 13, 2024, 12:22 | Insight
Key Highlights from KCRS24 by Sumanta K. Pal
Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in Boston focused…
Jun 26, 2024, 03:43 | Blog
Roberto Iacovelli: Honour to have TIDE-A commented by Laurence Albiges, Tom Powles and Dr. Wells
Roberto Iacovelli shared a post on X: "Great honor to have TIDE-A commented by Laurence…
Jun 13, 2024, 07:21 | Blog
Sumanta K. Pal: Looking forward to joining Roger Li and Vikram M. Narayan for a quick ASCO24 update
Sumanta K. Pal shared a post on X: "Looking forward to joining Roger Li and Vikram…
Jun 9, 2024, 02:45 | Insight
Brian Rini: KIM-1 is a novel prognostic and predictive biomarker in RCC
Toni Choueiri shared a post by Brian Rini, Chief of Clinical Trials at Vanderbilt University, on X/Twitter:…
May 29, 2024, 12:36 | Blog
Cristiane D. Bergerot: Looking forward to Laurence Albiges ' presentation at  ASCO24
Cristiane D. Bergerot shared on X/Twitter: "Looking forward to Laurence Albiges' presentation at ASCO24 on…
May 28, 2024, 07:49 | Insight
Tom Powles: Renal cancer highlights at ASCO24 - KIM1 biomarker data stands out
Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and…
May 25, 2024, 07:09 | Societies
Neeraj Agarwal summarizes some Abstracts of ASCO24
Neeraj Agarwal shared on X: Abstract #5010 by Michael Morris Phase 1 study of Actinium-225-labeled…
Feb 2, 2024, 17:53 | Blog
Laurence Albiges: Proud of Gustave Roussy GU group celebrating 20th anniversary GU24  
Laurence Albiges, Chair at Medical Oncology Department at Gustave Roussy, shared a post on X/Twitter:…
Feb 1, 2024, 17:14 | Insight
Sumanta K. Pal: She has developed what I think should be called the 'Bergerot QOL Index ' for kidney cancer
Sumanta K. Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared…
Jan 29, 2024, 17:32 | Insight
David Braun: Could really change how nivo is delivered in the future
David Braun, Oncologist, physician-scientist at Yale Cancer Center, shared a post on X/Twitter: "Really nice…
Dec 12, 2023, 12:40 | Societies
20 Posts Not To Miss From ESMO Asia Congress 2023
The ESMO Asia Congress 2023 took place in Singapore from 1 to 3 December. Our…
Oct 22, 2023, 00:11 | Blog
Maite Bourlon: Press release on CheckMate-67T study of subcutaneous Nivolumab while The European Society for Medical Oncology (ESMO) begins
Maite Bourlon, Urology Oncologist at the National Institute of Medical Sciences and Nutrition Salvador Zubirán,…
All: 29 Posts: 1 - 100
Special Coverage